Literature DB >> 33824931

Liver transplantation for rare liver diseases and rare indications for liver transplant.

Michele Finotti1, Pasquale Auricchio1, Alessandro Vitale1, Enrico Gringeri1, Umberto Cillo1.   

Abstract

Liver transplantation (LT) is currently considered the gold standard treatment for end-stage liver failure. Compared to the first decades of its use, LT is associated with lower comorbidity and mortality, with a 5-year survival over 70%. Worldwide, liver cirrhosis and hepatocellular carcinoma represent the major indications to LT. However, almost 1% of LT is performed for rare diseases or rare indications, which include non-hepatocellular malignancy, vascular disorders, metabolic and congenital liver disorders. These diseases can lead to hepatocellular necrosis, biliary tree abnormality and/or hepatomegaly. Most of these diseases are not associated with liver failure but in highly selected patients, LT represent an effective therapy improving the overall survival and quality of life. Rare indications for LT often overlap with rare diseases. However, rare LT indications for non-rare diseases are rising in the last decades, especially for benign primary liver tumor, colon rectal liver metastasis, neuroendocrine liver metastasis, and cholangiocarcinoma (CCA). Non-rare diseases with rare indication for LT and rare adult disease with an indication for LT are categorized and discussed in detail, focusing on some disorders for which the literature provides a more definitive evidence base. Early referral to a transplant center is encouraged to provide an effective therapeutic option in these non-standard indications for LT. 2021 Translational Gastroenterology and Hepatology. All rights reserved.

Entities:  

Keywords:  Rare indication; liver failure; liver metastases; oncology transplantation

Year:  2021        PMID: 33824931      PMCID: PMC7829071          DOI: 10.21037/tgh-19-282

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  3 in total

Review 1.  [Liver metastases of neuroendocrine tumors].

Authors:  S Nadalin; M Peters; A Königsrainer
Journal:  Chirurgie (Heidelb)       Date:  2022-06-17

Review 2.  Imaging of fibropolycystic liver disease.

Authors:  Kedar Sharbidre; Mohd Zahid; Sudhakar Kundapur Venkatesh; Chandra Bhati; Neeraj Lalwani
Journal:  Abdom Radiol (NY)       Date:  2022-06-07

3.  Identification of key genes and infiltrating immune cells among acetaminophen-induced acute liver failure and HBV-associated acute liver failure.

Authors:  Min Shi; Zhuyi Zhou; Zhongxia Zhou; Lijuan Shen; Jianbo Shen; Guoxiong Zhou; Renfei Zhu
Journal:  Ann Transl Med       Date:  2022-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.